Head-to-head · WeighScore
Transparent Meds vs Zealthy
The verdict
Transparent Meds takes it — 61.9/100 to 46.7/100.
Transparent Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Transparent Meds is an online GLP-1 weight-care service that connects you with licensed medical providers and leads with upfront pricing: compounded weekly injections of semaglutide at an intro $149/month…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Transparent Meds | Zealthy |
|---|---|---|
| WeighScore | 61.9/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #282 | #496 |
| Semaglutide | $229/mo (promotional rate, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $349/mo (compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #282 · C
Strengths
- Transparent, upfront monthly pricing — intro $149/mo for compounded semaglutide and $249/mo for tirzepatide (regular $229 / $349)
- Clean, modern telehealth experience with a quick eligibility quiz and clinician review before any prescription
- HIPAA-compliant and displays a LegitScript-style verification seal
Where it loses points
- Headline prices are intro first-month fees — the regular monthly cost is higher ($229 semaglutide, $349 tirzepatide)
- Connector model that pairs you with licensed providers; it doesn't name its compounding pharmacy
- Doesn't publish the states it serves, so confirm availability before signing up
- Compounded semaglutide and tirzepatide injections only — no oral, brand-name, or insurance options
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.